drugset / Trial / NCT01017042

Pharmacokinetic Study of an Acute Gout Regimen

NCT01017042

Phase 1 Completed 13 enrolled Mutual Pharmaceutical Company, Inc.
Non-randomizedSingle-groupOpen-labelBasic science

Summary

This study aims to characterize the pharmacokinetic profile of colchicine after a regimen of 1.8 mg over two hours. A secondary goal is to evaluate the safety and tolerability of this regimen in healthy volunteers. To this end, all study subjects will be monitored for adverse effects throughout the entire study period.

Timeline

Start
2007-09
Primary completion
2007-09
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Colchicine Small molecule 1.8 mg Oral

Indications

No indication recorded.